The FDA advisory panel voted 7-2, with one member abstaining, that the probable benefits of Grail Inc.'s Galleri test outweigh its risks for patients meeting the proposed criteria.

From the articleFDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It WorksAlso in Grail’s Blood Test to Detect Multiple Cancers Wins FDA Panel Backing, Grail multicancer detection test wins FDA advisers’ backing, FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks, FDA panel endorses first-of-a-kind cancer blood test from Grail, Grail multicancer detection test wins FDA advisers’ backing